2 publishers · first seen Thu, 29 Oct 2026 11:10 UTC · updated Thu, 29 Oct 2026 13:56 UTC
Laurus Labs reported a consolidated net profit of Rs 441 crore for the second quarter ended September 2026, more than double the Rs 195 crore recorded in the same period the previous year. The company's revenue from operations rose 33 per cent year-on-year to Rs 2,206 crore, up from Rs 1,653 crore. The growth was driven by its CDMO and Affordable Medicine segments, with strong EBITDA margins at 34.5 per cent.
Laurus Labs entered into agreements to acquire a 60 per cent stake in Canada-based Galenvs Science and a 52 per cent stake in SI&C Resins. The moves aim to strengthen its capabilities in oligonucleotides, peptide-resin technology, and integrated CDMO services. The company has operationalised its first commercial-scale peptide plant in Vizag, with further capacity expansion underway.
Content auto-generated. May contain inaccuracies.